Annual Cancer Symposium - 2010 Scientific Program - Saturday Sessions

Go To: Wednesday's Sessions | Thursday's Sessions | Friday's Sessions | Saturday's Sessions | Sunday's Sessions | All Posters

Meet the Professor Breakfasts

6:30 – 7:30 am Saturday Registration Required • Fee: $45 • Limit: 30 per breakfast

B10 Damage Control: Managing Extremely Difficult Intra-Operative Scenarios in Surgical Oncology
(Renaissance Hotel – Landmark 3)
John F. Gibbs, MD* Lawrence D. Wagman, MD** *Disclosure: None **Disclosure: Consultant: Medwaves, Inc.; Honorarium: AngioDynamics, Inc.

B11 Breast Cancer: Maximizing Cure While Preserving the Aesthetic Breast
(Renaissance Hotel – Landmark 2)
Lisa A. Newman, MD, MPH Disclosure: None

B12 Principles of Surgical Management of Hepatic Metastases (Renaissance Hotel – Landmark 1)
Michael I. D’Angelica, MD Disclosure: None

B13 Establishing and Maintaining a Surgical Oncology Translational Research Program
(Renaissance Hotel – Landmark 5)
William G. Cance, MD Disclosure: None

B14 Extremity Sarcoma: Principles of Management
(Renaissance Hotel – Landmark 6)
Kelly K. Hunt, MD Disclosure: Speaker: Novartis

B15 International Perspective: Indications, Techniques, and Outcomes of Radical Lymph Node Dissections for Upper GI Malignancies in Japan (Renaissance Hotel – Landmark 7)
Masaki Mori, MD, PhD Disclosure: None

B16 Surgical Oncology Outreach in the Developing World: Lessons Learned & Next Steps
(Renaissance Hotel – Majestic C)
Rosemary B. Duda, MD, MPH Disclosure: None

B17 Melanoma: Optimal Evidence-Based
Management, 2010
(Renaissance Hotel – Majestic B)
Keith A. Delman, MD* Jonathan S. Zager, MD** *Disclosure: None **Disclosure: Consultant, Advisory Board: Perfusion Sciences, Inc; Speaker: Pfizer and Esiai Inc.

B18 Everything the Surgical Oncologist Needs to Know About Sample Size Computations
(Renaissance Hotel – Majestic A)
Ulrich Guller, MD
Disclosure: None

Objectives: At the conclusion of this session, participants should be able to: (B10) provide examples of the most common challenging scenarios in hepatobiliary surgery; (B11) describe options for aesthetic breast surgery; discuss risks of aesthetic breast surgery; and explain advantages of aesthetic breast surgery; (B12) review major controversies in the management of metastatic colorectal cancer to the liver; (B13) review the strategies and pitfalls for developing and maintaining a translational cancer research laboratory; (B14) review the multidisciplinary management of extremity sarcomas; (B15) demonstrate the diagnosis and treatment of upper GI tract cancers in Japan and discuss the detail of lymph node dissection of gastric or esophageal cancers; (B16) discuss surgical oncology in resource limited countries; discuss how we as a Society may help our colleagues in these areas; discuss the need for accurate data on prevalence of cancers; and share the experiences of assisting local hospitals develop their cancer programs; (B17) discuss the approach to difficult scenarios in melanoma including stage III, intransit and liver (stage IV) disease; identify the role of surgery in advanced stages of melanoma; identify the novel approaches available for the surgical management of complicated melanoma patients; and discuss the options for some of the clinical trials and experimental therapies for patients with melanoma; and (B18) explain the use, importance, and caveats of sample size computations for cancer research.

Plenary Session III

7:45 – 8:45 am Saturday Room 221-228 • America’s Center

Moderator: Monica Morrow, MD
Disclosure: None

7:45 am Present Day Local-Regional Recurrence Rates (LRR) in Patients with T1 and T2 Breast Cancer (BC) with 0 and 1 to 3 Lymph Node (LN) Metastases Following Mastectomy without Radiation (47)
         R. Sharma,1* I. Bedrosian,1 A. Lucci,1 R.F. Hwang,1
  Rourke,1 T.A. Buchholz,2 W. Qiao,3
  MericBernstam,1 A.M. GonzalezAngulo,4
  Kronowitz,5 G.V. Babiera,1 E.A. Mittendorf,1
  Krishnamurthy,6 K.K. Hunt,1 H.M. Kuerer.1

1. MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX; 2. MD Anderson Cancer Center, Department of Radiation Oncology, Houston, TX; 3. MD Anderson Cancer Center, Department of Biostatistics, Houston, TX; 4. MD Anderson Cancer Center, Department of Breast Medical Oncology, Houston, TX; 5. MD Anderson Cancer Center, Department of Plastic Surgery, Houston, TX; 6. MD Anderson Cancer Center, Department of Pathology, Houston, TX.
Disclosure: None

8:00 am Final Results of a Prospective Multi-Center Phase II Trial of Systemic ADH-1 in Combination with Melphalan via Isolated Limb Infusion (M-ILI) in Patients with Advanced Extremity Melanoma (48)
  Beasley,1* N. McMahon,1 G. Sanders,1
  Coleman,1 J. Padussis,1 J.S. Zager,2

S.N. Hochwald,3 S.R. Grobmyer,3 B. Peterson,1
W.P. Peters,4 R. Royal,5 M.I. Ross,5 D.S. Tyler.1
1. Duke University, Durham, NC; 2. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;
3. University of Florida, Gainesville, FL; 4. Adherex Technologies, Inc., Durham, NC; 5. University of Texas MD Anderson Cancer Center, Houston, TX.
Disclosure: None
* designated presenter

8:15 am Diagnostic and Prognostic Significance of FOXC1 Expression in Basal-Like Triple Negative Breast Cancer (49)
  Ray,1* J. Wang,2 Y. Qu,2 M. ShinSim,3
  Shamonki,4 S.P. Bagaria,1 B. Liu,6 D. Elashoff,5

D.S. Hoon,2 A.E. Giuliano,1 X. Cui.2 1. Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA; 2. Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA; 3. Department of Biostatistics, John Wayne Cancer Institute, Santa Monica, CA;
4. Department of Pathology, Saint John's Health Center, Santa Monica, CA; 5. Division of General Internal Medicine, School of Medicine, University of California at Los Angeles, Los Angeles, CA;
6. Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China.
Disclosure: None

8:30 am Comparisons of Demographics, Burnout and Career Satisfaction of 407 Surgical Oncologists (SO) with 7454 Surgeons from Other Specialties: An American College of Surgeons (ACS) Survey (50)
C. Balch,1* T.D. Shanafelt,2 J. Sloan,2 H.M. Kuerer.3
1. Surgery, Johns Hopkins, Baltimore, MD; 2. Mayo Clinic, Rochester, MN; 3. Univ. of Texas MD Anderson Cancer Center, Houston, TX.
Disclosure: None
Objectives: Upon completion of this session, participants should be able to: (47) critically evaluate presentday localregional breast cancer recurrence rates to better gauge the potential benefit of post mastectomy radiation therapy in women with 13 lymph node metastases treated in the current era; (48) analyze the results of this clinical trial which utilizes a novel therapeutic agent in the treatment of advanced extremity melanoma;
(49) discuss the diagnostic and prognostic significance of FOXC1 expression in basallike triple negative breast cancer; and (50) review potential sources of distress in their surgical oncology career compared to other surgical specialties.

8:45 – 9:00 am

2008–2010 Clinical Investigator Award Presentations

Room 221-228 • America’s Center

Moderator: Kenneth K. Tanabe, MD

Disclosure: Sanofi Aventis, Schering, Institute for Medical Education Research – Speaker; Covidien, Morningside
Technology LLC, LEK Consulting – Consultant; Up To Date, Pfizer, Vertex Pharmaceuticals – Honorarium

Combining Targeted Biological Agents with Radiation Therapy for Soft Tissue Sarcomas
Sam S. Yoon, MD
University of Pennsylvania
Disclosure: None

Cyst Fluid Protein Expression Profiling for the Identification of High-Risk Intraductal Papillary Mucinous Neoplasms of the Pancreas
Peter J. Allen, MD
Memorial Sloan-Kettering Cancer Center
Disclosure: None

9:00 – 9:45 am

James Ewing Lecture
Surgical Oncology in the Genomic Era: Doing More with Less

Richard L. Schilsky, MD
Professor of Medicine, Biological Sciences Division
University of Chicago. Chicago, IL
Disclosure: None

Objectives: Upon completion of this session, participants should be able to: a) illustrate the impact of advances in cancer biology on surgical oncology practice and research; b) discuss the importance of evidence-based medicine to the introduction of new surgical techniques; and c) review the role of surgical oncologists in
dissemination of proven surgical advances into community practice and assessment of their comparative effectiveness.

Supported by an educational grant from the James Ewing Foundation

9:45 – 10:15 am Refreshment Break in Exhibit Hall

Plenary Session IV

10:15 – 11:15 am Saturday

Room 221-228 • America’s Center

Moderator: V. Suzanne Klimberg, MD
Disclosure: Stocks: AngioDynamics

10:15 am A Nomogram for Predicting the Risk of Local Recurrence After Breast Conserving Surgery for DCIS (51)
K.J. Van Zee*, U. Rudloff, L.M. Jacks, J.I. Goldberg,
C.A. Wynveen, E. Brogi, S. Patil. Memorial SloanKettering Cancer Center, New York, NY.
Disclosure: None

10:30 am Phase II Comparison Study of Intraoperative Autotransfusion for Major Oncologic Procedures (52)
M. Bower,* S. Ellis, C.R. Scoggins, K.M. McMasters,
R.C. Martin. Surgical Oncology, University of Louisville, Louisville, KY.
Disclosure: None

10:45 am Sentinel Node Biopsy and Immediate Lymphadenectomy for Occult Metastases versus Nodal Observation and Delayed Lymphadenectomy for Nodal Recurrence: Fourth Interim Analysis of MSLT-I (53)
D. Morton,1* J.F. Thompson,2 A.J. Cochran,3
R. Elashoff.3 1. John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA;
2. Sydney Melanoma Unit, Camperdown, NSW, Australia; 3. University of California at Los Angeles, Los Angeles, CA.
Disclosure: None

11:00 am Primary Hyperparathyroidism with Negative Preoperative Imaging Still Most Commonly Caused by a Solitary Parathyroid Adenoma (54)
R. Lewis,* K. Ebede, D. Han, D.L. Fraker. Surgery, University of Pennsylvania Health System, Philadelphia, PA.
Disclosure: None
* designated presenter

Objectives: Upon completion of this session, participants should be able to: (51) describe the need for improved risk stratification in women with noninvasive breast cancer and explain the value of nomograms as tools for individual risk estimation; (52) assess the benefits of intraoperative autotranfusion in patients undergoing major oncologic resections; (53) discuss the advantages of minimally invasive surgical staging of regional lymph nodes in patients with clinically localized cutaneous melanoma; and (54) recognize the interaction between the distribution of pathology in primary hyperparathyroidism and the predictive value of preoperative imaging studies.

11:15 am – Noon

John Wayne Clinical Research Lecture
Colorectal Cancer Outcome Improvement in Europe: Updated Results of Trials and Population-Based Outcome Registration

Cornelis J. H. van de Velde, MD, PhD
Professor of Surgery
President European Society of Surgical
Oncology
Leiden, The Netherlands
Disclosure: None

Objectives: Upon completion of this session, participants should be able to: describe the basic principles of colorectal cancer surgery and multidisciplinary management and discuss the results of colorectal cancer audit programs in Europe.

Supported by an educational grant from the John Wayne Foundation

Noon – 1:00 pm Complimentary Lunch & Poster Viewing in Exhibit Hall

Cast your vote for the Best Science and Clinical Posters.
Ballots must be submitted by 1:00 pm Saturday.

Parallel Session…Parallel Session…Parallel Session…
Cancer Forum II

1:00 – 3:00 pm Saturday

Room 240 • America’s Center

Moderators: Jason B. Fleming, MD* and David C. Linehan, MD**
*Disclosure: None **Disclosure: Research Grant: Novartis Oncology

1:00 pm beta-catenin is a Promising Therapeutic Target in Dedifferentiated Liposarcoma (55)
A.M. Crago,* P. DeCarolis, C. Antonescu, N. Socci,
S. Singer. Surgery, Memorial SloanKettering Cancer Center, New York, NY. Disclosure: None
Discussant: Kerrington D. Smith, MD Disclosure: None

1:15 pm Molecular Profiles of Pancreatic Cystic Neoplasms: The K-homology Domain Containing Protein (KOC) May Be an Accurate Test for Malignant Cystic Lesions (56)
A. Briggs,* R. Wilcox, A.E. Noffsinger, J.C. Barreto,
M.C. Posner, K.K. Roggin. Surgery, University of Chicago, Chicago, IL.
Disclosure: None Discussant: Matthew Katz, MD Disclosure: None

1:30 pm Paradoxical Effects of Smo Proto-Oncogene Overexpression in Hepatocytes (57)
J.K. Sicklick,1* J. Wang,2 J. Huang,2 W. Chen,2
A.M. Diehl.2 1. Surgery, Memorial SloanKettering Cancer Center, New York, NY; 2. Gastroenterology, Duke University Medical Center, Durham, NC.
Disclosure: None Discussant: Eugene Choi, MD Disclosure: None

* designated presenter

1:45 pm Epiregulin mRNA Expression in Colorectal Hepatic Metastases is Associated with Survival Post Partial Hepatectomy (58)
M.B. Smith,* A.S. Caudle, L.S. Caskey, M.O. Meyers, D.T. Moore, B.F. Calvo. University of North Carolina Hospitals GI SPORE GRANT P50 CA 106991, Chapel Hill, NC.
Disclosure: None Discussant: Syed Ahmad, MD Disclosure: None

2:00 pm Peritoneal Lavage with Distilled Water is Tumoricidal: Science or Legend? (59)
F. Ito,* M. Seshadri, E. Ong, M. Alassas,
J.M. Kane III, J.J. Skitzki. Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY.
Disclosure: None Discussant: Carsten T. Viehl, MD Disclosure: None

2:15 pm Perioperative Immunotherapy is Protective Against Melanoma Recurrence in a Mouse Model (60)
  Bellavance,* J.E. McCracken, J. O'Sullivan,
  Zloza, F. Kohlhapp, M.C. Posner, J.A. GuevaraPatino. Surgery, University of Chicago, Chicago, IL. Disclosure: None
Discussant: William Gillanders, MD Disclosure: None

2:30 pm Apo2L/TRAIL Inhibits Growth of Patient Pancreatic Tumors in a Metastasizing Orthotopic Xenograft SCID Mouse Model (61)
R. Sharma,* S. Buitrago, R. Pitoniak, J.F. Gibbs,
B.L. Hylander, E.A. Repasky. Roswell Park Cancer Institute, Buffalo, NY.
Disclosure: None Discussant: William G. Hawkins, MD Disclosure: Honorarium: DC Bead; Speaker: Novartis

* designated presenter

Objectives: Upon completion of this session, participants should be able to: (55) describe how signaling pathways regulating normal adipogenesis are altered in liposarcoma cells; (56) characterize the immunohistochemical phenotypes across the spectrum of pancreatic cystic neoplasms; (57) discuss the effects of Hedgehog signaling and the Smoothened protooncogene in normal hepatocytes and hepatomas; (58) explain the human epidermal growth factor receptor family as it relates to metastatic colorectal cancer; (59) discuss available methods of peritoneal lavage in the field of surgical oncology; (60) discuss the role of immune memory responses in perioperative DNA vaccination and discuss the mechanisms for the induction of immune responses against tumorassociated antigens; and (61) describe the advantages of patient xenograft models for evaluating anticancer therapies, compare the results obtained in subcutaneous vs. orthotopic locations, discuss death receptor pathways and their role in apoptosis, and assess the potential of Apo2L/TRAIL for the treatment of pancreatic cancer.

3:00 – 3:30 pm Refreshments, Cookies and Poster Discussion in Exhibit Hall

* designated presenter

Parallel Session…Parallel Session…Parallel Session…
Gastrointestinal Cancer

1:00 – 3:00 pm Saturday

Room 221-228 • America’s Center

Moderators: Ronald P. DeMatteo, MD* and Herbert C. Hoover, Jr., MD**
*Disclosure: Consultant, Advisory Board, Speaker, Honorarium: Novartis **Disclosure: Consultant, Advisory Board, Speaker: Vaccinogen, Inc.

1:00 pm FN1 is an Independent Prognostic Marker and a Susceptible Indicator of Chemotherapy in Esophageal Cancer (62)
T. Sudo,1* K. Mimori,1 T. Yokobori,1 M. Iwatsuki,1
F. Tanaka,1 M. Mori.2 1. Medical Institute of Bioregulation, Kyushu University, Beppu, Japan;
2. Department of Surgery, Graduate School of Medicine, Osaka University, Suita, Japan.
Disclosure: None

1:15 pm Chemotherapy After Portal Vein Embolization Protects Against Tumor Growth During Liver Hypertrophy Prior to Hepatectomy for Cancer (63)
         C. Fischer, W. Jarnagin, K. Brown, M. D'Angelica,
A. Covey, R. DeMatteo, S. Tuorto, L. Schwartz,
G. Gatrejdman, N. Kemeny, Y. Fong.* Department of Surgery, Memorial SloanKettering Cancer Center, New York, NY.
Disclosure: None

1:30 pm Precision Hepatic Arterial Irinotecan Therapy in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: Optimal Tolerance and Prolonged Overall Survival (64)
S.C. Schiffman,* C.R. Scoggins, K.M. McMasters,
R.C. Martin. University of Louisville, Louisville, KY. Disclosure: None

1:45 pm Defining Venous Involvement in Borderline Resectable Pancreatic Cancer (65)
Y. Chun,* J.C. Watson, B.N. Milestone,
J.P. Hoffman. Fox Chase Cancer Center, Philadelphia, PA.
Disclosure: None
* designated presenter

2:00 pm Lymph Node Resection in Laparoscopic Distal Pancreatectomy is Equivalent to the Open Operation (66)
N. Newman,* B.H. Edil, M.A. Makary. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.
Disclosure: None

2:15 pm Intra-arterial Iodine-131-Lipiodol for Unresectable Hepatocellular Carcinoma (67)
T.C. Chua,* F. Chu, S.P. Butler, R.J. Quinn, D. Glenn,
D.L. Morris. University of New South Wales Department of Surgery, St George Hospital, Sydney, NSW, Australia.
Disclosure: None

2:30 pm Resection for Klatskin Tumors: Curative or Palliative? (68)
  Cannon,1* M. Thomas,1 K. Bilinski,1
  Kaikaus,1 K. Ravindra,1 S. Rudich,2 S. Appana,1
  Barve,1 T. Doty,2 T. Shaquor,1 G. Brock,1
  Marvin,1 S. Barve,1 C. McClain,1 W. Jones,1

K. McMasters,1 J.F. Buell.1 1. Surgery, University of Louisville, Louisville, KY; 2. University of Cincinatti, Cincinatti, OH.
Disclosure: None

2:45 pm ANN Analysis to Identify MicroRNA Expression Patterns in Colorectal Cancer (69)
K. Chang,1* N. Miller,1 E. Kheirelseid,1 G. Ball,2
  Smith,1 M. Regan,1 O.J. McAnena,1
  Kerin.1 1. Surgery, National University of Ireland, Galway, Galway, Ireland; 2. Nottingham Trent University, Nottingham, United Kingdom.

Disclosure: None

Objectives: Upon completion of this session, participants should be able to: (62) clarify the clinical role of FN1 as a metastatic marker as well as a susceptible marker for chemotherapy in esophageal cancer; (63) discuss the issues affecting tumor growth related to portal vein embolization; (64) discuss the safety, efficacy and survival benefit of drugeluting bead (DEB) therapy in unresectable intrahepatic cholangiocarcinoma; (65) identify the degree of venous impingement that constitutes borderline resectability in pancreatic adenocarcinoma; (66) discuss available surgical options for distal pancreas cancer, summarize the advantages of laparoscopic distal pancreatectomy, and consider recommending laparoscopic distal pancreatectomy to select patients with distal pancreas cancer; (67) identify Iodine131Lipiodol as a therapeutic strategy in unresectable hepatocellular carcinoma and recognize its role as a palliative treatment for this disease entity; (68) discuss the modern surgical management of hilar cholangiocarcinoma, with particular focus on the role of hepatic resection; and (69) describe the role of microRNA dysregulation in colorectal cancer, and their potential roles as novel diagnostic biomarkers, prognostic indicators and therapeutic targets.

3:00 – 3:30 pm Refreshments, Cookies and Poster Discussion in Exhibit Hall
* designated presenter

Order Session DVDs HERE while supplies last

Parallel Session…Parallel Session…Parallel Session…
Breast Cancer

1:00 – 3:00 pm Saturday

Room 220 • America’s Center

Moderators: Lisa A. Newman, MD, MPH* and Michael S. Sabel, MD**
*Disclosure: None **Disclosure: Speaker, Honorarium, Research Grant: Schering

1:00 pm Distribution of Axillary Lymph Node Metastases in Breast Cancer Predicts Mortality Better Than the Number of Positive Nodes (70)
J.W. Jakub,* K.L. Bryant, M. Huebner, T.L. Hoskin,
J.C. Boughey, C. Reynolds, A.C. Degnim. Surgery, Mayo Clinic, Rochester, MN.
Disclosure: None

1:15 pm Double-Blinded, Placebo Controlled Prospective Randomized Trial Evaluating the Efficacy of Continuous Paravertebral Catheter Anesthesia with Paravertebral Block in Breast Cancer Surgery (71)
         C.C. Buckenmaier III,1 K.H. Kwon,1 R.S. Howard,2
G.M. McKnight,1 C.D. Shriver,3 A. Stojadinovic.3*
1 Regional Anesthesia and Pain Management Initiative, Anesthesia & Operative Service, Walter Reed Army Medical Center, Washington, DC;
2 Department of Clinical Investigation, Division of Biostatistics, Walter Reed Army Medical Center, Washington, DC; 3. Clinical Breast Care Project, Walter Reed Army Medical Center, Washington, DC.
Disclosure: None

1:30 pm Contralateral Prophylactic Mastectomy is Associated with a Survival Advantage in High-Risk Women with a Personal History of Breast Cancer (72)
         J.C. Boughey,1* T.L. Hoskin,2 T.A. Sellers,3
A.C. Degnim,1 M.J. Kasner,4 L.C. Hartmann,5
M.H. Frost.4 1. Surgery Mayo Clinic, Rochester, MN; 2. Biomedical Statistics Mayo Clinic, Rochester, MN; 3. Moffitt Cancer Center, Tampa, FL;
4. Women's Cancer Program Mayo Clinic, Rochester, MN; 5. Medical Oncology Mayo Clinic, Rochester, MN.
Disclosure: None
* designated presenter

1:45 pm Margin Index: A New Method for Prediction of Residual Disease Following Breast-Conserving Surgery (73)
J.A. Margenthaler,1* F. Gao,1 V.S. Klimberg.2
1. Department of Surgery, Washington University School of Medicine, Saint Louis, MO; 2. University of Arkansas for Medical Sciences, Little Rock, AR.
Disclosure: None

2:00 pm Breast Cancer Risk in Women with Pseudoangiomatous Stromal Hyperplasia (PASH) (74)
         A. Degnim,1* D.A. Visscher,2 R.A. Vierkant,1
J.C. Boughey,1 D.C. Radisky,3 S.S. Anderson,1
V.S. Pankratz,1 M. Frost,1 L.C. Hartmann.1 1. Mayo Clinic, Rochester, MN; 2. University of Michigan, Ann Arbor, MN; 3. Mayo Clinic, Jacksonville, FL.
Disclosure: None

2:15 pm Risk Factors for False Negative (FN) Sentinel Lymph Node (SLN) Biopsy Performed After Neoadjuvant Chemotherapy (NeoCTX) in Patients Presenting with Node-Positive Breast Cancer (75)
A. Kolli,* T.M. Breslin, M.S. Sabel, K.M. Diehl,
V.M. Cimmino, A.E. Chang, L.A. Newman.
University of Michigan, Ann Arbor, MI.
          Disclosure: None

2:30 pm Tumor Sampling Variables Affect Reproducibility of Predictive Gene Expression Signatures in Breast Cancer (76)
B.R. Untch,* M. Abdelgadir Adam, C.L. Tebbit,
J.R. Marks, J.A. Olson. Surgery, Duke University Medical Center, Durham, NC.
Disclosure: None

2:45 pm Metaplastic Breast Cancer: To Radiate or Not to Radiate? (77)
W.H. Tseng,* S.R. Martinez. Surgical Oncology, University of California at Davis, Sacramento, CA.
Disclosure: None
* designated presenter

Objectives: Upon completion of this session, participants should be able to: (70) explain the impact of non sentinel lymph node involvement on survival and recurrence in breast cancer patients; (71) discuss the role of continuous paravertebral catheter anesthesia in patients undergoing operative treatment for breast cancer and summarize the advantages, disadvantages, and limitations of the technique in clinical practice for postoperative pain; (72) explain the association between contralateral prophylactic mastectomy and overall survival; (73) discuss predictors of margin status following breastconserving surgery; (74) explain the breast cancer risk associated with pseudoangiomatous stromal hyperplasia; (75) identify markers for inaccurate identification of sentinel lymph node after administration of neoadjuvant chemotherapy; (76) identify various factors that can influence the application of gene expression signatures; and (77) discuss prognostic factors and surgical treatment of metaplastic breast cancer and discuss the role of radiation therapy for metaplastic breast cancer.

3:00 – 3:30 pm Refreshments, Cookies and Poster Discussion in Exhibit Hall

Parallel Session…Parallel Session…Parallel Session…
Sarcoma

1:00 – 3:00 pm Saturday Room 230-231 • America’s Center

Moderators: Hong Jin Kim, MD* and Chandrajit P. Raut, MD, MSc**
*Disclosure: Speaker: SanofiAventis, Genzyme; Advisory Board: Genzyme **Disclosure: Advisory Board, Honorarium: Novartis
1:00 pm Treatment of Advanced Dermatofibrosarcoma Protuberans (DFSP) with Imatinib Mesylate and with or without Surgical Resection (78)
P. Rutkowski,1* M. DebiecRychter,2 Z.I. Nowecki,1
M. Zdzienicki,1 W. Ruka.1 1. Soft Tissue/Bone Sarcoma and Melanoma, Cancer CenterInstitute Warsaw, Warsaw, Poland; 2. Catholic University of Leuven, Leuven, Belgium.
Disclosure: Advisory Board: Novartis, Honorarium: Novartis

1:15 pm Paclitaxel-Eluting Polymer Film Reduces Locoregional Recurrence in Mouse Model of Sarcoma: A Novel Investigational Therapy (79)
         R. Liu,1* J.E. Wade,1 J.B. Wolinsky,2 J.H. Winer,1
P.J. Catalano,3 A.J. Wagner,3 M.W. Grinstaff,2
Y.L. Colson,1 C.P. Raut.1 1. Brigham and Women's Hospital, Boston, MA; 2. Boston University, Boston, MA; 3. DanaFarber Cancer Institute, Boston, MA.
Disclosure: None

1:30 pm Dermatofibrosarcoma Protuberans (DFSP): Predictors of Recurrence and Response to Neoadjuvant Therapies (80)
R.C. Fields,* S. Singer, M.F. Brennan. Department of Surgery, Memorial SloanKettering Cancer Center, New York, NY.
Disclosure: None

1:45 pm Limb Preservation with Isolated Limb Infusion for Unresectable Non-melanoma Cutaneous and Soft Tissue Malignancies (81)
         K.K. Turaga,1* G.M. Beasley,2 R.J. Gonzalez,1
K.A. Delman,3 G.D. Letson,1 D. Cheong,1
D.S. Tyler,2 J.S. Zager.1 1. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; 2. Duke University, Durham, NC; 3. Emory University, Atlanta, GA.
Disclosure: None
* designated presenter …continued on next page
Parallel Session…Parallel Session…Parallel Session…

2:00 pm Revisiting the Role of Surgery in the Management of Abdominal Desmoid Tumors (82)
S. Siddique,* R. Kandel, C.J. Swallow, R.A. Gladdy.
Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada.
Disclosure: None

2:15 pm Testicular/Scrotal Soft Tissue Sarcomas: Confusing Presentation and Diverse Biologic Behavior (83)
R.D. Bennett,2 J.M. Kane.1* 1. Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY;
2. University at Buffalo School of Medicine, Buffalo, NY.
Disclosure: None

2:30 pm Dose Reduction in Isolated Limb Perfusion for Soft Tissue Sarcoma of the Extremities is Safe and Effective in Terms of Long-term Patient Outcome (84)
M.L. HovenGondrie,* E. Bastiaannet, R.J. Van Ginkel, A.J. Suurmeijer, H.J. Hoekstra. University Medical Center Groningen, Groningen, Netherlands.
Disclosure: None

2:45 pm Conditional Survival of Extremity Soft Tissue Sarcoma: Results Beyond the Staging System (85)
H.M. Parsons,1* W.B. AlRefaie,2 T.M. Tuttle,1
E.B. Habermann.1 1. Department of Surgery, University of Minnesota, Minneapolis, MN;
2. Minneapolis Veteran Affairs Medical Center, Minneapolis, MN.
Disclosure: None

Objectives: Upon completion of this session, participants should be able to: (78) discuss the current role of imatinib in treatment of advanced dermatofibrosarcoma protuberans harboring t(17;22) and explain how Imatinib therapy leads in some cases to longterm responses and may result in resectability of the tumor or diminishing possible disfiguring; (79) discuss the efficacy of implantation of paclitaxelloaded polymer film in reducing locoregional recurrence of sarcoma in a mouse model; (80) identify factors associated with diseasefree survival in the treatment of Dermatofibrosarcoma Protuberans (DFSP); and identify the different types of and indications for nonsurgical therapy for Dermatofibrosarcoma Protuberans (DFSP); (81) discuss the outcomes of the use of Isolated limb infusions for nonmelanoma skin and soft tissue malignancies; (82) identify that abdominal desmoids have an excellent outcome and thus surgery should be limited to patients who are symptomatic and fail periods of observation and/or nonoperative intervention; (83) explain the behavior and treatment of soft tissue sarcomas that present in the testicular or scrotal area; (84) discuss the impact of TNFdose reduction in Isolated Limb Perfusion for Soft Tissue Sarcoma of the extremities in terms of longterm patient outcome; and (85) identify factors associated with conditional sarcoma specific survival in surgically treated nonmetastatic extremity soft tissue sarcoma patients.

3:00 – 3:30 pm Refreshments, Cookies and Poster Discussion in Exhibit Hall

Parallel Session…Parallel Session…Parallel Session…
Quality Improvement/Clinical Outcomes

1:00 – 3:00 pm Saturday

Room 232 • America’s Center

Moderators: Martin D. McCarter, MD* and Dennis L. Rousseau, Jr., MD, PhD**
*Disclosure: Consultant: Covidien; Speaker: Institute for Medical Education and Research **Disclosure: None

1:00 pm Prognostic Value of Pain and Quality of Life in Patients with Locally Recurrent Rectal Cancer (86)
Y. You,* H. Habiba, G.C. Chang, M.A. RodriguezBigas, J.M. Skibber. University of Texas MD Anderson Cancer Center, Houston, TX.
Disclosure: None

1:15 pm Preoperative Factors Predict Morbidity After Pancreaticoduodenectomy: Creation of a NSQIP Nomogram (87)
D.Y. Greenblatt,* E. Winslow, V. Rajamanickam,
R. Rettammel, C.S. Cho, S.M. Weber. Department of Surgery, University of Wisconsin, Madison, WI.
Disclosure: None

1:30 pm Assessment of ACS-NSQIP's Predictive Ability for Adverse Events after Major Cancer Surgery (88)
         D. BorjaCacho,1* H.M. Parsons,1 E.B. Habermann,1
D.A. Rothenberger,1 W.G. Henderson,2
W.B. AlRefaie.1 1. Surgery, University of Minnesota, Minneapolis, MN; 2. University of Colorado, Aurora, CO.
Disclosure: None

1:45 pm Minimally Invasive Surgery is Underutilized for Colorectal Disease (89)
         C.N. Robinson,* G.J. Chen, C.J. Balentine,
C.L. Marshall, D. Anaya, A. Artinyan, D. Albo,
D.H. Berger. Baylor College of Medicine, Houston, TX.
Disclosure: None
* designated presenter

2:00 pm Improving on National Quality Indicators of Breast Cancer Care in a Large Public Hospital as a Means to Decrease Disparities for African-American Women (90)
M. Rizzo,1* H. Bumpers,2 J. Okoli,2 D. SeniorCrosby,3 S. Hearn,3 R. O'Reagan,4 A. Zelnak,4
S.G. Patterson,2 S.G. Gabram.1 1. Department of Surgery Emory University School of Medicine, Atlanta, GA; 2. Department of Surgery Morehouse University School of Medicine, Atlanta, GA; 3. Avon Comprehensive Breast Center at Grady, Atlanta, GA;
4. Hematology Oncology Winship Cancer Center, Atlanta, GA.
Disclosure: None

2:15 pm Comparison of a Novel Favorable Pathology Model with Stage (Clinical or Pathologic) or Biopsy Gleason Score for Predicting Biochemical Recurrence (91)
M.J. Donovan,* F. Khan, V. Zubek, D. Powell,
J. Alter. Aureon Laboratories, Yonkers, NY. Disclosure: Employee: Aureon Laboratories

2:30 pm Standardization and Documentation of Surgical and Pathologic Variables in a Multi-Institutional Trial of Adjuvant Therapy for Pancreatic Cancer: Results From ACOSOG Z5031 (92)
  Katz,1* N.B. Merchant,2 S. Brower,3
  Campbell,4 M. Posner,5 L.W. Traverso,6
R.A. Abrams,7 V.J. Picozzi,6 P.W. Pisters.8 1. Surgery, UC Irvine, Orange, CA; 2. Vanderbilt University Medical Center, Nashville, TN; 3. Memorial Health University Medical Center, Savannah, GA; 4. Mayo Clinic, Rochester, MN; 5. University of Chicago, Chicago, IL; 6. Virginia Mason Medical Center, Seattle, WA; 7. Rush University Medical Center, Chicago, IL; 8. UTMD Anderson Cancer Center, Houston, TX.
Disclosure: None
* designated presenter

2:45 pm Individual Item Analysis of Quality of Life Assessments Related to Laparoscopicassisted Colectomy in the COST Trial 93-46-53 (INT 0146) (93)
         C.H. Stucky,1* B.A. Pockaj,1 P.A. Novotny,2
J.A. Sloan,2 D.J. Sargent,2 M.J. O'Connell,3
R.W. Beart,4 J. Skibber,5 H. Nelson,2 J.C. Weeks.6
1. General Surgery, Mayo Clinic Arizona, Phoenix, AZ; 2. Mayo Clinic Rochester, Rochester, MN;
1 Allegheny General Hospital, Pittsburgh, PA;
2 University of Southern California, Los Angeles, CA; 5. MD Anderson, Houston, TX; 6. DanaFarber Cancer Institute, Boston, MA.
Disclosure: None

Objectives: Upon completion of this session, participants should be able to: (86) discuss the value in assessing pain and quality of life in patients receiving surgical and nonsurgical treatments for locally recurrent rectal cancer; (87) discuss the rate of serious complications after pancreaticoduodenectomy in the ACS NSQIP database as well as the risk factors associated with serious complications; (88) discuss the utility and current limitations of ACS NSQIP to predict adverse events after major cancer surgery; (89) explain that minimally invasive surgery is underutilized for colorectal disease; (90) identify National Quality Indicators for Breast Cancer Care regarding radiation therapy and adjuvant chemotheraphy; (91) explain how integrating clinical and biometric characteristics of a biopsy sample improves BCR prediction over solely employing pretreatment clinical characteristics; (92) describe the limitations of current multiinstitutional trials of adjuvant therapy for pancreatic cancer and discuss the critical need for improving surgical and pathologic quality control among patients enrolled on such trials; and (93) identify the improvements in quality of life after laparoscopicassisted colectomy for colon cancer.

3:00 – 3:30 pm Refreshments, Cookies and Poster Discussion in Exhibit Hall

Poster Discussion Session

3:00 – 3:30 pm Saturday Exhibit Hall
This session will allow for meaningful discussion and constructive critique of recent research findings. More than 300 posters will be displayed. Authors will be present.

Susan G. Komen for the Cure® Symposium
Controversies in the Management of Young Women with Breast Cancer

3:30 – 5:00 pm Saturday

Room 221-228 • America’s Center

Supported by an educational grant from Susan G. Komen for the Cure®

Moderator: Monica Morrow, MD
Disclosure: None

3:30 pm New Insights into the Prevention and Treatment of Familial Breast Cancer
David Euhus, MD
Professor of Surgery Marilyn R. Corrigan Distinguished Chair in Breast Cancer Surgery Medical Director, Clinical Cancer Genetics University of Texas Southwestern Medical Center Dallas, TX
Disclosure: None (OffLabel Use of Treatments)

3:50 pm Selecting Local Therapy in the Young Breast Cancer Patient
Tari A. King, MD
Associate Attending Surgeon, Breast Service Jeanne A. Petrek Junior Faculty Chair Memorial SloanKettering Cancer Center Assistant Professor of Surgery Weill Medical College of Cornell New York, NY
Disclosure: None

4:10 pm Management of Pregnant Women with Breast Cancer -Epidemiology and Local Therapy
Armando E. Giuliano, MD
Chief of Science and Medicine John Wayne Cancer Institute Santa Monica, CA
Disclosure: None

4:30 pm Management of Pregnant Women with Breast
Cancer -Systemic Therapy, Fertility after Treatment
Eric P. Winer, MD
Thompson Investigator in Breast Cancer Research Chief, Division of Women's Cancers DanaFarber Cancer Institute Professor of Medicine Harvard Medical School Boston, MA
Disclosure: Advisory Board: Ariad; Research Grant: Genentech

4:50 pm Panel Discussion/Questions

Objectives: At the conclusion of this session, participants should be able to: a) discuss the advances in the identification and management of women at increased risk of breast cancer development due to genetic mutations; b) explain differences in the risk of local recurrences on the basis of age seen after breast conserving surgery and mastectomy and be aware of factors that modify these risks; c) determine the incidence of breast cancer in pregnant women and appropriate strategies for diagnosis and surgical management; and d) discuss approach to adjuvant systemic therapy in the pregnant woman with breast cancer and the long term effects of such treatment or fertility.

Potential Therapeutic Targets for Clinical Trials

3:30 – 5:00 pm Saturday

Room 220 • America’s Center

Partially supported by an educational grant from Genentech BioOncology

Moderator: Hong Jin Kim, MD
Disclosure: Speaker: SanofiAventis, Genzyme; Advisory Board: Genzyme

3:30 pm Overview from Novel Agents Task Force of the NCI-src Inhibition Wells Messersmith, MD Head, GI Medical Oncology University of Colorado Denver Aurora, CO
Disclosure: Advisory Board: Genentech; Research Grant: Pfizer; Honorarium: Genentech, OSI

3:50 pm PARP Inhibition and Breast Cancer
Cynthia Osborne, MD
Breast Medical Oncology Baylor Charles A. Sammons Cancer Center Dallas, TX
Disclosure: None (OffLabel Use of Treatments)

4:10 pm Potential Drugs and Targets along the Hedgehog Signaling Cascade in Pancreatic Cancer and Other Solid Tumors Sarah P. Thayer, MD, PhD Assistant Professor of Surgery Massachusetts General Hospital & Harvard Medical School
W. Gerald Austen Scholar in Academic Surgery Director, Pancreatic Biology Laboratory Department of Surgery Massachusetts General Hospital Boston, MA
Disclosure: None

4:30 pm Targets Along the Ras Pathway, RalGTP Inhibition
Jen Jen Yeh, MD
Assistant Professor University of North Carolina Chapel Hill, NC
Disclosure: None

4:50 pm Panel Discussion/Questions

Objectives: At the conclusion of this session, participants should be able to: a) determine signaling targets that are emerging for future clinical trials; b) discuss the importance of a multidisciplinary approach between surgical oncology, medical oncology, pharmaceutical industry, and basic science; c) describe an overview of the goals of the NCI Novel Agents Task Force; d) summarize the promising targets along several pathways, including Ras/ralGTP, PARP and apoptosis, hedgehog, and src; and e) explain some of the limitations to evaluating novel targeting agents in the current cooperative clinical trials groups.

Go To: Wednesday's Sessions | Thursday's Sessions | Friday's Sessions | Saturday's Sessions | Sunday's Sessions | All Posters